Blog
RSS FeedPosted by Michael Wonder on 27 Feb 2024
Voxelotor for the treatment of patients with sickle cell disease (draft guidance)
27 February 2024 - NICE has issued further draft guidance on the use of voxelotor following an appeal hearing in ...
Posted by Michael Wonder on 27 Feb 2024
Tafamidis for the treatment of patients with transthyretin amyloidosis with cardiomyopathy
27 February 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 26 Feb 2024
Setmelanotide acetate for the treatment of people with obesity and hyperphagia associated with Bardet-Biedl syndrome (draft guidance)
22 February 2024 - NICE has published further draft guidance on the use of setmelanotide acetate. ...
Posted by Michael Wonder on 24 Feb 2024
Drug insurance: a single payer pharmacare program would jeopardise coverage quality for 21 million Canadians
22 February 2024 - Imposing a single payer universal drug insurance plan on all Canadians would jeopardise coverage quality for ...
Posted by Michael Wonder on 22 Feb 2024
Busy dad with leukaemia getting 'outdated treatment'
23 February 2024 - A West Coast dad is receiving “outdated treatment” for his leukaemia because PHARMAC’s policies are blocking ...
Posted by Michael Wonder on 22 Feb 2024
A cancer doctor’s view of why reform of PHARMAC is vital
23 February 2024 - Late last year, many of my colleagues returned from the largest international gathering of doctors who ...
Posted by Michael Wonder on 22 Feb 2024
Up to 14,000 people could benefit from the first treatment for severe alopecia recommended by NICE
22 February 2024 - Thousands of people with severe hair loss due to alopecia areata are set to benefit from a ...
Posted by Michael Wonder on 22 Feb 2024
COVID-19 vaccine available in March
22 February 2024 - Joint media release with Health New Zealand. ...
Posted by Michael Wonder on 21 Feb 2024
Talazoparib tosylate for the treatment of patients with advanced BRCA mutation positive HER2 negative breast cancer (final guidance)
21 February 2024 - NICE has published final evidence-based recommendations on the use of talazoparib tosylate (Talzenna) for the treatment ...
Posted by Michael Wonder on 15 Feb 2024
Updates to the HTA review research and analysis papers collection: emerging health technologies
15 February 2024 - The draft paper 'Emerging Health Technologies' developed to support the deliberations of the HTA Review Reference ...
Posted by Michael Wonder on 15 Feb 2024
More than 30,000 people to benefit under PHARMAC proposal
15 February 2024 - PHARMAC is proposing to fund five treatments to improve the lives of over 30,000 people in New ...
Posted by Michael Wonder on 13 Feb 2024
PHARMAC to fund new treatments for breast and blood cancer
14 February 2024 - PHARMAC is funding two new cancer treatments, for advanced breast cancer, and for blood cancer, which will ...
Posted by Michael Wonder on 13 Feb 2024
SMC - February 2024 decisions
12 February 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...
Posted by Michael Wonder on 11 Feb 2024
Desperate PHARMAC plea from family selling cans for unfunded myeloma cancer drugs
11 February 2024 - Multiple myeloma, a common blood cancer, is incurable, but can be survived for years with the right ...
Posted by Michael Wonder on 10 Feb 2024
Isatuximab in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed and refractory multiple myeloma
9 February 2024 - NICE is reviewing its guidance on the use of isatuximab for the treatment of patients with ...